Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 208-214 , July 2010

Pleural Malignancies

  • Joseph S. Friedberg, MD

      Affiliations

    • Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA
    • ,
  • Keith A. Cengel, MD, PhD

      Affiliations

    • Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA
    • Corresponding Author InformationAddress reprint requests to Keith A. Cengel, MD, PhD, Department of Radiation Oncology, University of Pennsylvania School of Medicine, 180G John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104

References 

  1. Vallieres E, Shepherd FA, Crowley J, et al. The IASLC lung cancer staging project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:1049–1059
  2. Wagenfeld L, Zeitz O, Richard G. Visual loss after povidone-iodine pleurodesis. N Engl J Med. 2007;357:1264–1265
  3. Dresler CM, Olak J, Herndon JE, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127:909–915
  4. Kuzniar TJ, Blum MG, Kasibowska-Kuzniar K, et al. Predictors of acute lung injury and severe hypoxemia in patients undergoing operative talc pleurodesis. Ann Thorac Surg. 2006;82:1976–1981
  5. Warren WH, Kalimi R, Khodadadian LM, et al. Management of malignant pleural effusions using the Pleur(x) catheter. Ann Thorac Surg. 2008;85:1049–1055
  6. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007–3013
  7. Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: A phase II prospective study. J Thorac Cardiovasc Surg. 2009;138:405–411
  8. Zellos L, Richards WG, Capalbo L, et al. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009;137:453–458
  9. Forster KM, Smythe WR, Starkschall G, et al. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: Clinical implementation. Int J Radiat Oncol Biol Phys. 2003;55:606–616
  10. Aokage K, Yoshida J, Ishii G, et al: The impact on survival of positive intraoperative pleural lavage cytology in patients with non-small-cell lung cancer. J Thorac Cardiovasc Surg 2009 (in press)
  11. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644
  12. Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: Bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12:713–718
  13. Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol. 1994;12:1156–1163
  14. Yellin A, Simansky DA, Paley M, et al. Hyperthermic pleural perfusion with cisplatin: Early clinical experience. Cancer 92. 2001;2197:2197–2203
  15. McAleer MF, Tsao AS, Liao Z. Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2009;75:326–337
  16. Yajnik S, Rosenzweig KE, Mychalczak B, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;56:1319–1326
  17. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006;65:640–645
  18. Lee C, Bayman N, Swindell R, et al. Prophylactic radiotherapy to intervention sites in mesothelioma: A systematic review and survey of UK practice. Lung Cancer. 2009;66:150–156
  19. Friedberg JS. Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21:177–187
  20. Cengel KA, Hahn SM. Photodynamic therapy. In:  DeVita V,  Lawrence T,  Tosenberg S editor. Cancer: Principles and Practice of Oncology. (ed 8). Philadelphia, PA: Lippincott Williams and Wilkins; 2008;p. 767–774
  21. Pass HI, Temeck BK, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol. 1997;4:628–633
  22. Friedberg JS, Mick R, Stevenson J, et al. A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg. 2003;75:952–959
  23. Schouwink H, Ruevekamp M, Oppelaar H, et al. Photodynamic therapy for malignant mesothelioma: Preclinical studies for optimization of treatment protocols. Photochem Photobiol. 2001;73:410–417
  24. Friedberg JS, Mick R, Stevenson JP, et al. Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J Clin Oncol. 2004;22:2192–2201
  25. Pass HI, Donington JS. Use of photodynamic therapy for the management of pleural malignancies. Semin Surg Oncol. 1995;11:360–367
  26. Sterman DH, Recio A, Carroll RG, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: High rate of antitumor immune responses. Clin Cancer Res. 2007;13:4456–4466
  27. Lucchi M, Chella A, Melfi F, et al. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2007;31:529–533

PII: S1053-4296(10)00017-2

doi: 10.1016/j.semradonc.2010.01.009

Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 208-214 , July 2010

Article Tools

* Image Usage & Resolution